Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/235449
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Haploidentical transplantation in high‐risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)

AutorPérez-Martínez, Antonio; Ferreras, Cristina; Pascual, Antonia; González-Vicent, Marta; Alonso, Laura; Badell, Isabel; Fernández Navarro, José María CSIC; Regueiro, Alexandra; Plaza, Mercedes; Pérez-Hurtado, José M. CSIC; Benito, Ana M. CSIC ORCID ; Beléndez, Cristina; Couselo, José Miguel; Fuster, José Luis; Díaz‐Almirón, Mariana; Bueno, David; Mozo, Yasmina; Marsal, Julia; Gómez-López, Alicia; Sisinni, Luisa; Díaz de Heredia, Cristina; Díaz, Miguel Ángel
Fecha de publicaciónene-2020
EditorJohn Wiley & Sons
CitaciónAmerican Journal of Hematology 95(1): 28-37 (2020)
ResumenA total of 192 pediatric patients, median age 8.6 years, with high‐risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo‐HSCT) using post‐transplantation cyclophosphamide (PT‐Cy), or ex vivo T cell‐depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers in Spain. Some 41 patients received an unmanipulated graft followed by PT‐Cy for graft‐vs‐host disease (GvHD) prophylaxis. A total of 151 patients were transplanted with CD3‐depleted peripheral blood stem cells (PBSCs) by either CD34+ selection, CD3+CD19+ depletion, TCRαβ+CD19+ depletion or CD45RA+ depletion, added to CD34+ selection for GvHD prophylaxis. The PBSCs were the only source in patients following ex vivo TCD haplo‐HSCT; bone marrow was the source in 9 of 41 patients following PT‐CY haplo‐HSCT. Engraftment was achieved in 91.3% of cases. A donor younger than 30 years, and the development of chronic GvHD were positive factors influencing survival, whereas positive minimal residual disease (MRD) before transplant and lymphoid disease were negative factors. The probability of relapse increased with lymphoid malignancies, a donor killer‐cell immunoglobulin‐like receptor (KIR) haplotype A and positive MRD pretransplant. No difference was found in overall survival, disease‐free survival or relapse incidence between the two platforms. Relapse is still of concern in both platforms, and it should be the focus of future efforts. In conclusion, both platforms for haplo‐HSCT were effective and could be utilized depending on the comfort level of the center.
Versión del editorhttp://doi.org/10.1002/ajh.25661
URIhttp://hdl.handle.net/10261/235449
DOI10.1002/ajh.25661
Identificadoresdoi: 10.1002/ajh.25661
issn: 0361-8609
e-issn: 1096-8652
Aparece en las colecciones: (IBIS) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

Page view(s)

108
checked on 28-mar-2024

Download(s)

16
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.